Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis
Some commonly available patient or disease characteristics may be associated with progression-free survival (PFS) and overall survival (OS) in EGFR-mutant non-small cell lung cancer (NSCLC) patients receiving EGFR-TKIs (epidermal growth factor receptor - tyrosine kinase inhibitors). We performed a s...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-08-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/11/9/1259 |
| _version_ | 1797762045113794560 |
|---|---|
| author | Carlo Buonerba Simona Iaccarino Pasquale Dolce Martina Pagliuca Michela Izzo Luca Scafuri Ferdinando Costabile Vittorio Riccio Dario Ribera Brigitta Mucci Simone Carrano Fernanda Picozzi Davide Bosso Luigi Formisano Roberto Bianco Sabino De Placido Giuseppe Di Lorenzo |
| author_facet | Carlo Buonerba Simona Iaccarino Pasquale Dolce Martina Pagliuca Michela Izzo Luca Scafuri Ferdinando Costabile Vittorio Riccio Dario Ribera Brigitta Mucci Simone Carrano Fernanda Picozzi Davide Bosso Luigi Formisano Roberto Bianco Sabino De Placido Giuseppe Di Lorenzo |
| author_sort | Carlo Buonerba |
| collection | DOAJ |
| description | Some commonly available patient or disease characteristics may be associated with progression-free survival (PFS) and overall survival (OS) in EGFR-mutant non-small cell lung cancer (NSCLC) patients receiving EGFR-TKIs (epidermal growth factor receptor - tyrosine kinase inhibitors). We performed a systematic review and meta-analysis of randomized control trials (RCTs) to explore differences in outcomes associated with EGFR-TKIs among subgroups of EGFR-mutant NSCLC patients. Pooled HRs for progression or death (PFS-HRs) and pooled HRs for death (OS-HRs) were compared among sub-groups defined according to baseline clinical and demographic variables as well as type of EGFR mutation. In the entire assessable population of 4465 EGFR-mutant NSCLC patients, significant interactions with PFS were found for gender (males vs. females; pooled ratio of the PFS-HRs = 1.2; 95% CI 1.12–1.56), smoking history (smokers vs. non-smokers; pooled ratio of the PFS-HRs = 1.26; 95% CI 1.05–1.51), and type of EGFR mutation (patients with exon 21 L858R mutation vs. exon 19 deletion; pooled ratio of the PFS-HRs = 1.39; 95% CI 1.18–1.63). Male patients, smokers and patients with EGFR exon 21 L858R mutation may derive less benefit from EGFR-TKIs compared to female patients, non-smokers and patients with EGFR exon 19 deletion. |
| first_indexed | 2024-03-12T19:21:44Z |
| format | Article |
| id | doaj.art-496a2edceec4418faed41f8030e7755d |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T19:21:44Z |
| publishDate | 2019-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-496a2edceec4418faed41f8030e7755d2023-08-02T05:04:15ZengMDPI AGCancers2072-66942019-08-01119125910.3390/cancers11091259cancers11091259Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-AnalysisCarlo Buonerba0Simona Iaccarino1Pasquale Dolce2Martina Pagliuca3Michela Izzo4Luca Scafuri5Ferdinando Costabile6Vittorio Riccio7Dario Ribera8Brigitta Mucci9Simone Carrano10Fernanda Picozzi11Davide Bosso12Luigi Formisano13Roberto Bianco14Sabino De Placido15Giuseppe Di Lorenzo16Regional Reference Center for Rare Tumors, Department of Oncology and Hematology, AOU Federico II of Naples, 80131 Naples, ItalyDepartment of Clinical Medicine and Surgery, University Federico II of Naples, Via Pansini 5, 80131 Naples, ItalyDepartment of Public Health, Federico II University of Naples, 80131 Naples, ItalyDepartment of Clinical Medicine and Surgery, University Federico II of Naples, Via Pansini 5, 80131 Naples, ItalyDepartment of Clinical Medicine and Surgery, University Federico II of Naples, Via Pansini 5, 80131 Naples, ItalyDepartment of Clinical Medicine and Surgery, University Federico II of Naples, Via Pansini 5, 80131 Naples, ItalyDepartment of Clinical Medicine and Surgery, University Federico II of Naples, Via Pansini 5, 80131 Naples, ItalyDepartment of Clinical Medicine and Surgery, University Federico II of Naples, Via Pansini 5, 80131 Naples, ItalyDepartment of Clinical Medicine and Surgery, University Federico II of Naples, Via Pansini 5, 80131 Naples, ItalyDepartment of Clinical Medicine and Surgery, University Federico II of Naples, Via Pansini 5, 80131 Naples, ItalyDepartment of Clinical Medicine and Surgery, University Federico II of Naples, Via Pansini 5, 80131 Naples, ItalyDepartment of Clinical Medicine and Surgery, University Federico II of Naples, Via Pansini 5, 80131 Naples, ItalyDepartment of Clinical Medicine and Surgery, University Federico II of Naples, Via Pansini 5, 80131 Naples, ItalyDepartment of Clinical Medicine and Surgery, University Federico II of Naples, Via Pansini 5, 80131 Naples, ItalyDepartment of Clinical Medicine and Surgery, University Federico II of Naples, Via Pansini 5, 80131 Naples, ItalyDepartment of Clinical Medicine and Surgery, University Federico II of Naples, Via Pansini 5, 80131 Naples, ItalyDepartment of Clinical Medicine and Surgery, University Federico II of Naples, Via Pansini 5, 80131 Naples, ItalySome commonly available patient or disease characteristics may be associated with progression-free survival (PFS) and overall survival (OS) in EGFR-mutant non-small cell lung cancer (NSCLC) patients receiving EGFR-TKIs (epidermal growth factor receptor - tyrosine kinase inhibitors). We performed a systematic review and meta-analysis of randomized control trials (RCTs) to explore differences in outcomes associated with EGFR-TKIs among subgroups of EGFR-mutant NSCLC patients. Pooled HRs for progression or death (PFS-HRs) and pooled HRs for death (OS-HRs) were compared among sub-groups defined according to baseline clinical and demographic variables as well as type of EGFR mutation. In the entire assessable population of 4465 EGFR-mutant NSCLC patients, significant interactions with PFS were found for gender (males vs. females; pooled ratio of the PFS-HRs = 1.2; 95% CI 1.12–1.56), smoking history (smokers vs. non-smokers; pooled ratio of the PFS-HRs = 1.26; 95% CI 1.05–1.51), and type of EGFR mutation (patients with exon 21 L858R mutation vs. exon 19 deletion; pooled ratio of the PFS-HRs = 1.39; 95% CI 1.18–1.63). Male patients, smokers and patients with EGFR exon 21 L858R mutation may derive less benefit from EGFR-TKIs compared to female patients, non-smokers and patients with EGFR exon 19 deletion.https://www.mdpi.com/2072-6694/11/9/1259non-small cell lung cancerepidermal growth factor receptor tyrosine kinase inhibitorssex |
| spellingShingle | Carlo Buonerba Simona Iaccarino Pasquale Dolce Martina Pagliuca Michela Izzo Luca Scafuri Ferdinando Costabile Vittorio Riccio Dario Ribera Brigitta Mucci Simone Carrano Fernanda Picozzi Davide Bosso Luigi Formisano Roberto Bianco Sabino De Placido Giuseppe Di Lorenzo Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis Cancers non-small cell lung cancer epidermal growth factor receptor tyrosine kinase inhibitors sex |
| title | Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis |
| title_full | Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis |
| title_fullStr | Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis |
| title_short | Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis |
| title_sort | predictors of outcomes in patients with egfr mutated non small cell lung cancer receiving egfr tyrosine kinase inhibitors a systematic review and meta analysis |
| topic | non-small cell lung cancer epidermal growth factor receptor tyrosine kinase inhibitors sex |
| url | https://www.mdpi.com/2072-6694/11/9/1259 |
| work_keys_str_mv | AT carlobuonerba predictorsofoutcomesinpatientswithegfrmutatednonsmallcelllungcancerreceivingegfrtyrosinekinaseinhibitorsasystematicreviewandmetaanalysis AT simonaiaccarino predictorsofoutcomesinpatientswithegfrmutatednonsmallcelllungcancerreceivingegfrtyrosinekinaseinhibitorsasystematicreviewandmetaanalysis AT pasqualedolce predictorsofoutcomesinpatientswithegfrmutatednonsmallcelllungcancerreceivingegfrtyrosinekinaseinhibitorsasystematicreviewandmetaanalysis AT martinapagliuca predictorsofoutcomesinpatientswithegfrmutatednonsmallcelllungcancerreceivingegfrtyrosinekinaseinhibitorsasystematicreviewandmetaanalysis AT michelaizzo predictorsofoutcomesinpatientswithegfrmutatednonsmallcelllungcancerreceivingegfrtyrosinekinaseinhibitorsasystematicreviewandmetaanalysis AT lucascafuri predictorsofoutcomesinpatientswithegfrmutatednonsmallcelllungcancerreceivingegfrtyrosinekinaseinhibitorsasystematicreviewandmetaanalysis AT ferdinandocostabile predictorsofoutcomesinpatientswithegfrmutatednonsmallcelllungcancerreceivingegfrtyrosinekinaseinhibitorsasystematicreviewandmetaanalysis AT vittorioriccio predictorsofoutcomesinpatientswithegfrmutatednonsmallcelllungcancerreceivingegfrtyrosinekinaseinhibitorsasystematicreviewandmetaanalysis AT darioribera predictorsofoutcomesinpatientswithegfrmutatednonsmallcelllungcancerreceivingegfrtyrosinekinaseinhibitorsasystematicreviewandmetaanalysis AT brigittamucci predictorsofoutcomesinpatientswithegfrmutatednonsmallcelllungcancerreceivingegfrtyrosinekinaseinhibitorsasystematicreviewandmetaanalysis AT simonecarrano predictorsofoutcomesinpatientswithegfrmutatednonsmallcelllungcancerreceivingegfrtyrosinekinaseinhibitorsasystematicreviewandmetaanalysis AT fernandapicozzi predictorsofoutcomesinpatientswithegfrmutatednonsmallcelllungcancerreceivingegfrtyrosinekinaseinhibitorsasystematicreviewandmetaanalysis AT davidebosso predictorsofoutcomesinpatientswithegfrmutatednonsmallcelllungcancerreceivingegfrtyrosinekinaseinhibitorsasystematicreviewandmetaanalysis AT luigiformisano predictorsofoutcomesinpatientswithegfrmutatednonsmallcelllungcancerreceivingegfrtyrosinekinaseinhibitorsasystematicreviewandmetaanalysis AT robertobianco predictorsofoutcomesinpatientswithegfrmutatednonsmallcelllungcancerreceivingegfrtyrosinekinaseinhibitorsasystematicreviewandmetaanalysis AT sabinodeplacido predictorsofoutcomesinpatientswithegfrmutatednonsmallcelllungcancerreceivingegfrtyrosinekinaseinhibitorsasystematicreviewandmetaanalysis AT giuseppedilorenzo predictorsofoutcomesinpatientswithegfrmutatednonsmallcelllungcancerreceivingegfrtyrosinekinaseinhibitorsasystematicreviewandmetaanalysis |